Association between eating disorders and functional gastrointestinal disorders: a systematic review
Abstract
Introduction: Functional gastrointestinal disorders (FGIDs) and eating disorders (EDs) frequently coexist with one another. It is not unusual for a patient to present with both diseases because they share many similarities with reference to the deeper psychological factors and the connection between the gastrointestinal tract and the brain. Many studies have shown that while the occurrence of FGID in eating disorder patients is noteworthy, it varies greatly, mostly due to disparate research approaches. This review aims to synthesize 2015-2025 evidence on ED-FGID associations, prevalence patterns, bidirectionality, shared psychological mechanisms, and implications for screening and multidisciplinary management.
Methods: In line with the PRISMA statement, this systematic review retrieved English-language research published within the period of 2015-2025 using a range of databases for studies related to the relationship between EDs and FGIDs. The quality of the observational studies with eligibility criteria met for data retrieval has been appraised using National Institutes of Health standards. The data has been narratively reported instead of meta-analyzed.
Results: The criteria are met in nine studies published between 2016 and 2025. The studies include both the cross-sectional type and the cohort type. The overall quality of the studies leans towards being sound. The trend indicates that the co-occurrence between EDs and FGIDs is prominent, with irritable bowel syndrome…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.